Lynx1 Capital Management LP and Weston Nichols Report Ownership in Neuphoria Therapeutics Inc.

Lynx1 Capital Management LP and Weston Nichols have reported their ownership in Neuphoria Therapeutics Inc. (NEUP) through a Form 3 filing with the SEC. Lynx1 Capital Management LP, acting as the investment manager for Lynx1 Master Fund LP, holds 236,218 shares of common stock in Neuphoria Therapeutics Inc. Weston Nichols, the sole member of Lynx1 Capital Management GP LLC, the general partner of Lynx1 Capital Management LP, also reports ownership of these shares. Both Lynx1 Capital Management LP and Weston Nichols disclaim beneficial ownership of the securities except to the extent of their pecuniary interest. The filing was signed on October 23, 2025, and the period of report is October 21, 2025.